Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 113

The DOI matches its Crossref record.

The Pharmacokinetics of Antiepileptic Drugs in Rats: Consequences for Maintaining Effective Drug Levels during Prolonged Drug Administration in Rat Models of Epilepsy

Löscher, Wolfgang · 2007 · Epilepsia

Abstract

Summary: Rodent models of chronic epilepsy with spontaneous recurrent seizures likely represent the closest parallel to the human condition. Such models may be best suited for therapy discovery for pharmacoresistant epilepsy and for antiepileptogenic or disease‐modifying therapeutics. However, the use of such rodent models for therapy discovery creates problems with regard to maintaining effective drug levels throughout a prolonged testing period. This is particularly due to the fact that rodents such as rats and mice eliminate most drugs much more rapidly than humans. Thus, knowledge about elimination rate of a test drug in a laboratory species is essential for development of a treatment paradigm that allows maintaining adequate drug levels in the system over the period of treatment. Currently, the most popular models of epilepsy with spontaneous seizures are poststatus epilepticus models of temporal lobe epilepsy in rats. Such models are both used for studies on antiepileptogenesis and drug resistance. For validation of these models, current antiepileptic drugs (AEDs) have to be used. In this article, the elimination rates of these AEDs and their effective plasma levels in rats are reviewed as a guide for developing treatment protocols for chronic drug testing. The advantages and disadvantages of several technologies for drug delivery are discussed, and some examples for calculation of adequate treatment protocols are given. As shown in this review, because of the rapid elimination of most AEDs in rats, it is no trivial task to maintain effective steady‐state AED levels in the plasma throughout the day over multiple days to ensure that there will be adequate levels in the system for the purpose of the experiment. However, the use of an adequate dosing regimen that is based on elimination rate is an absolute prerequisite when using rat models for discovery of new antiepileptogenic therapies or therapies for pharmacoresistant epilepsy, because otherwise such models may lead to erroneous conclusions about drug efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1528-1167.2007.01093.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 90

  1. Adusumalli VE, 1991, Felbamate pharmacokinetics in the rat, rabbit, and dog, Drug Metabolism and Disposal: the Biological Fate of Chemicals, 19, 1116
  2. Ali A, 2006, Effect of semi‐chronic carbamazepine treatment on spontaneous seizures in rats with kainate‐induced epilepsy: a drug‐in‐food method of AED administration, Epilepsia, 47, 297
  3. Ashley JJ, 1972, Inhibition of diphenylhydantoin elimination by its major metabolite, Res Commun Chem Pathol Pharmacol, 4, 297
  4. Atlas SA, 1980, Genetic differences in phenytoin pharmacokinetics: in vivo clearance and in vitro metabolism among inbred strains of mice, Dev Pharmacol Ther, 1, 281, 10.1159/000455547 · doi:10.1159/000455547
  5. Bartoszyk GD, 1986, New anticonvulsant drugs, 147
  6. 10.1080/0049825042000196749 · DOI
  7. Bertram E, 2005, Testing drugs for antiepileptic efficacy in a rat model of chronic limbic epilepsy, Epilepsia, 46, 281
  8. 10.1111/j.1528-1167.2007.00980.x · DOI
  9. Bhargava HN, 1995, Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies, NIDA Res Monogr, 147, 53
  10. 10.1212/WNL.32.10.1122 · DOI
  11. 10.1016/j.neuropharm.2006.05.021 · DOI
  12. 10.1111/j.0013-9580.2004.16904.x · DOI
  13. Browne TR, 2002, Antiepileptic drugs, 565
  14. 10.1111/j.2042-7158.1980.tb12861.x · DOI
  15. 10.1007/BF03190614 · DOI
  16. 10.1046/j.1472-8206.2002.00096.x · doi:10.1046/j.1472-8206.2002.00096.x
  17. 10.1016/j.ejphar.2003.09.065 · DOI
  18. 10.1177/106002809302700215 · DOI
  19. Dickinson RG, 1979, Disposition of valproic acid in the rat: dose‐dependent metabolism, distribution, enterohepatic recirculation and choleretic effect, J Pharmacol Exp Ther, 211, 583
  20. 10.1016/S0920-1211(98)00104-1 · DOI
  21. 10.1007/978-3-642-60072-2_23 · doi:10.1007/978-3-642-60072-2_23
  22. 10.1016/0006-8993(94)90631-9 · DOI
  23. Farghali H, 1976, Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects, Arch Int Pharmacodyn Ther, 220, 125
  24. File SE, 1993, Benzodiazepine withdrawal: behavioural pharmacology and neurochemical changes, Biochem Soc Symp, 59, 97
  25. 10.1016/S1461-5347(99)00162-5 · DOI
  26. Gerber N, 1971, Study of dose‐dependent metabolism of 5,5‐diphenyl‐hydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro, J Pharmacol Exp Ther, 178, 567
  27. 10.1097/00008877-199603000-00009 · DOI
  28. 10.1046/j.1528-1157.2002.18101.x · DOI · Paper page
  29. Grabenstatter HL, 2006, Effects of intraperitoneal and oral carbamazepine on spontaneous seizures in rats with kainate‐induced epilepsy, Epilepsia, 47, 306
  30. 10.1111/j.0013-9580.2005.13404.x · DOI
  31. Gram L, 1986, New anticonvulsant drugs, 229
  32. 10.1016/S0028-3908(00)00183-0 · doi:10.1016/s0028-3908(00)00183-0
  33. 10.1023/A:1015953715346 · doi:10.1023/a:1015953715346
  34. Holck HGO, 1937, Studies upon the sex‐difference in rats in tolerance to certain barbiturates and to nicotine, J Pharmacol Exp Ther, 60, 323
  35. 10.1016/0028-3908(89)90139-1 · DOI
  36. 10.1111/j.1528-1157.1995.tb01613.x · DOI
  37. 10.1007/BF00497022 · doi:10.1007/bf00497022
  38. 10.1080/009841096161960 · DOI
  39. 10.3109/00498258209038950 · doi:10.3109/00498258209038950
  40. Kato R, 1992, Sex‐specific cytochrome P450 as a cause of sex‐ and species‐related differences in drug toxicity, Toxicology Letters, 64
  41. 10.1002/ana.410050512 · doi:10.1002/ana.410050512
  42. 10.1016/0920-1211(94)00070-D · DOI
  43. Levy RH, 2002, Antiepileptic drugs
  44. 10.1002/hep.1840100417 · DOI · Paper page
  45. Löscher W, 1978, Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse, J Pharmacol Exp Ther, 204, 255
  46. 10.1016/0091-3057(86)90449-1 · doi:10.1016/0091-3057(86)90449-1
  47. 10.2165/00023210-200216100-00003 · DOI · Paper page
  48. Löscher W, 1978, Pharmacokinetics of sodium valproate in dog and mouse, Arzneimittel-Forsch, 28, 782
  49. 10.1016/0014-2999(89)90294-X · DOI
  50. 10.1111/j.1528-1157.1995.tb01637.x · DOI
  51. 10.1038/nrn1728 · DOI · Paper page
  52. 10.1016/0014-2999(90)90309-T · DOI
  53. 10.1016/0920-1211(88)90054-X · DOI · Paper page
  54. 10.1016/S0920-1211(02)00063-3 · DOI
  55. 10.1016/j.eplepsyres.2006.03.014 · DOI
  56. 10.1111/j.1528-1167.2006.00607.x · DOI · Paper page
  57. 10.1016/0014-4886(85)90026-3 · DOI
  58. 10.1016/0920-1211(90)90013-L · doi:10.1016/0920-1211(90)90013-l
  59. 10.1016/0920-1211(91)90075-Q · DOI · Paper page
  60. 10.1016/0920-1211(91)90062-K · DOI · Paper page
  61. 10.1111/j.1528-1157.1995.tb00993.x · doi:10.1111/j.1528-1157.1995.tb00993.x
  62. Löscher W, 1998, Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy, J Pharmacol Exp Ther, 284, 474, 10.1016/S0022-3565(24)37251-9 · DOI · Paper page
  63. Mattson RH, 2002, Antiepileptic drugs, 72
  64. 10.1615/CritRevNeurobiol.v12.i4.40 · DOI · Paper page
  65. 10.1111/j.1528-1157.1986.tb03572.x · DOI · Paper page
  66. 10.1258/002367792780809011 · doi:10.1258/002367792780809011
  67. 10.1016/0041-008X(85)90081-X · DOI · Paper page
  68. 10.1002/bdd.2510030405 · doi:10.1002/bdd.2510030405
  69. 10.1002/bdd.2510040209 · DOI
  70. 10.1515/CCLM.2004.245 · DOI · Paper page
  71. Patsalos PN, 2002, Antiepileptic Drugs, 428
  72. Perkins L, 1999, Encyclopedia of controlled drug delivery, version 2, 900
  73. 10.1016/0024-3205(88)90150-6 · DOI · Paper page
  74. 10.1016/S0920-1211(98)00074-6 · DOI
  75. Radulovic LL, 1995, Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys, Drug Metab Dispos, 23, 441
  76. 10.1016/0014-2999(92)90624-D · DOI
  77. Rundfeldt C, 1993, Anticonvulsant efficacy and adverse effects of phenytoin during chronic treatment in amygdala‐kindled rats, J Pharmacol Exp Ther, 266, 216
  78. 10.1016/S0920-1211(02)00069-4 · DOI
  79. 10.1016/0163-7258(88)90007-1 · DOI
  80. 10.1111/j.0013-9580.2003.32803.x · DOI · Paper page
  81. 10.1016/S0893-133X(00)00243-8 · DOI
  82. Taylor CP, 1986, New anticonvulsant drugs, 277
  83. 10.2165/00003495-200161080-00002 · DOI
  84. 10.1007/978-3-642-69518-6_19 · doi:10.1007/978-3-642-69518-6_19
  85. 10.1046/j.1365-2796.2000.00758.x · doi:10.1046/j.1365-2796.2000.00758.x
  86. Van Der Klejin, 1971, Pharmacokinetics of diazepam in dogs, mice and humans, Acta Pharmacol Toxicol (Copenh) 29 Suppl, 3, 109, 10.1111/j.1600-0773.1971.tb03291.x · doi:10.1111/j.1600-0773.1971.tb03291.x
  87. 10.1111/j.1528-1167.2006.00496.x · DOI · Paper page
  88. 10.1038/sj.bjp.0703337 · DOI
  89. 10.1016/j.seizure.2004.01.007 · DOI
  90. Welty D, 1997, Pharmacokinetics (PK) and pharmacodynamics (PD) of CI‐1009 (pregabalin) ans gabapentin in rats with maximal electroshock, Epilepsia, 38, 35

Cited by

See all 113

Metadata

Authors
Löscher, W.
Venue
Epilepsia
Publisher
Wiley
Published
2007-04-18
Volume
48
Issue
7
Pages
1245-1258
ISSN
  • 0013-9580
  • 1528-1167
Cited by
113
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Pharmacokinetics of Antiepileptic Drugs in Rats: Consequences for Maintaining Effective Drug Levels during Prolonged Drug Administration in Rat Models of Epilepsy. https://app.cochat.ai/papers/10.1111/j.1528-1167.2007.01093.x
The paper
Löscher, W. (2007). The Pharmacokinetics of Antiepileptic Drugs in Rats: Consequences for Maintaining Effective Drug Levels during Prolonged Drug Administration in Rat Models of Epilepsy. Epilepsia. https://doi.org/10.1111/j.1528-1167.2007.01093.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.